SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 747.61+6.3%10:46 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (2175)8/3/2017 11:31:06 AM
From: Miljenko Zuanic1 Recommendation

Recommended By
DewDiligence_on_SI

  Read Replies (1) of 3559
 
<I presume Miljenko is happy about sunset of SNY antibody collaboration>

Yes, it is. At the time when REGN needed extra $$$$ to push Abs discovery it was OK. Now, they can do it on its own and take full credits from REGN-genomic translation into Abs selection.

I checked REGN balance shits, and am happy that they improve it. Hope, it may stay that way. Eylea WW revenue will continue to increase in next few more years, NVS is not treat at all, and IF they can improve property and selection of the Abs in development....well, my retirement may continue to be healthy. :-)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News